Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Class
1.2.2. Treatment
1.2.3. Treatment
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug Class and Route of Administration Outlook
2.2.2. Distribution Channel Outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Schizophrenia Drugs Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Schizophrenia Drugs Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pricing Analysis
3.3.4. Pipeline Analysis
3.3.4.1. Phase 1
3.3.4.2. Phase 2
3.3.4.3. Phase 2
Chapter 4. Schizophrenia Drugs Market: Drug Class Estimates & Trend Analysis
4.1. Global Schizophrenia Drugs Market: Drug Class Dashboard
4.2. Global Schizophrenia Drugs Market: Drug Class Movement Analysis
4.3. Global Schizophrenia Drugs Market by Class, Revenue
4.4. Second-Generation Antipsychotics
4.4.1. Second-Generation Antipsychotics market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1. Risperdal (Risperidone)
4.4.1.1.1. Risperdal (Risperidone) market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2. Invega (Paliperidone)
4.4.1.2.1. Invega (Paliperidone) market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3. Zyprexa (Olanzapine)
4.4.1.3.1. Zyprexa (Olanzapine) market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.4. Geodon (Ziprasidone)
4.4.1.4.1. Geodon (Ziprasidone) market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.5. Seroquel (Quetiapine)
4.4.1.5.1. Seroquel (Quetiapine) market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.6. Latuda (Lurasidone)
4.4.1.6.1. Latuda (Lurasidone) market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.7. Aristada (Aripiprazole Lauroxil)
4.4.1.7.1. Aristada (Aripiprazole Lauroxil) market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.8. Fanapt (Iloperidone)
4.4.1.8.1. Fanapt (Iloperidone) market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.9. Vraylar (Cariprazine)
4.4.1.9.1. Vraylar (Cariprazine) market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Third-Generation Antipsychotics
4.5.1. Schizophrenia Drugs market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Schizophrenia Drugs Market: Route of Administration Estimates & Trend Analysis
5.1. Global Schizophrenia Drugs Market: Route of Administration Dashboard
5.2. Global Schizophrenia Drugs Market: Route of Administration Movement Analysis
5.3. Global Schizophrenia Drugs Market by Route of Administration , Revenue
5.4. Oral Antipsychotics
5.4.1. Oral Antipsychotics market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Injectable Antipsychotics
5.5.1. Injectable Antipsychotics market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Schizophrenia Drugs Market: Distribution Channel Estimates & Trend Analysis
6.1. Global Schizophrenia Drugs Market: Distribution Channel Dashboard
6.2. Global Schizophrenia Drugs Market: Distribution Channel Movement Analysis
6.3. Global Schizophrenia Drugs Market by Distribution Channel, Revenue
6.4. Hospital Pharmacies
6.4.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Retail Pharmacies
6.5.1. Retail Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Online Pharmacies
6.6.1. Online Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Others
6.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Schizophrenia Drugs Market: Regional Estimates & Trend Analysis by Drug Class, Distribution Channel, and Route of Administration
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2024
8.3.4. Johnson & Johnson Services, Inc.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Class benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Bristol-Myers Squibb Company/ Otsuka Holdings Co., Ltd.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Class benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Sumitomo Pharma Co., Ltd.
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Class benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Eli Lilly and Company
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Class benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Alkermes
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Class benchmarking
8.3.8.4. Strategic initiatives
8.3.9. VANDA PHARMACEUTICALS
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Class benchmarking
8.3.9.4. Strategic initiatives
8.3.10. AstraZeneca
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Class benchmarking
8.3.10.4. Strategic initiatives
8.3.11. AbbVie Inc.
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Class benchmarking
8.3.11.4. Strategic initiatives
8.3.12. Pfizer Inc.
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Class benchmarking
8.3.12.4. Strategic initiatives
8.3.13. H. Lundbeck A/S
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Class benchmarking
8.3.13.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America Schizophrenia Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 3 North America Schizophrenia Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 4 North America Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 5 U.S. Schizophrenia Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 6 U.S. Schizophrenia Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 7 U.S. Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 8 Canada Schizophrenia Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 9 Canada Schizophrenia Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 10 Canada Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 11 Mexico Schizophrenia Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 12 Mexico Schizophrenia Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 13 Mexico Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 14 Europe Schizophrenia Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 15 Europe Schizophrenia Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 16 Europe Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 17 Germany Schizophrenia Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 18 Germany Schizophrenia Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 19 Germany Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 20 UK Schizophrenia Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 21 UK Schizophrenia Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 22 UK Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 23 France Schizophrenia Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 24 France Schizophrenia Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 25 France Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 26 Italy Schizophrenia Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 27 Italy Schizophrenia Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 28 Italy Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 29 Spain Schizophrenia Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 30 Spain Schizophrenia Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 31 Spain Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 32 Asia Pacific Schizophrenia Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 33 Asia Pacific Schizophrenia Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 34 Asia Pacific Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 35 China Schizophrenia Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 36 China Schizophrenia Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 37 China Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 38 Japan Schizophrenia Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 39 Japan Schizophrenia Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 40 Japan Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 41 India Schizophrenia Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 42 India Schizophrenia Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 43 India Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 44 South Korea Schizophrenia Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 45 South Korea Schizophrenia Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 46 South Korea Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 47 Latin America Schizophrenia Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 48 Latin America Schizophrenia Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 49 Latin America Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 50 Brazil Schizophrenia Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 51 Brazil Schizophrenia Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 52 Brazil Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 53 MEA Schizophrenia Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 54 MEA Schizophrenia Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 55 MEA Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 56 South Africa Schizophrenia Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 57 South Africa Schizophrenia Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 58 South Africa Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 59 Saudi Arabia Schizophrenia Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 60 Saudi Arabia Schizophrenia Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 61 Saudi Arabia Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 62 UAE Schizophrenia Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 63 UAE Schizophrenia Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 64 UAE Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 65 Kuwait Schizophrenia Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 66 Kuwait Schizophrenia Drugs Market, by Route of Administration, 2018-2030 (USD Million)
Table 67 Kuwait Schizophrenia Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
List of Figures
Figure 1 Schizophrenia Drugs market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Value chain-based sizing & forecasting
Figure 6 QFD modelling for market share assessment
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Drug Class and Route of Administration segment snapshot
Figure 10 Route of Administration segment snapshot
Figure 11 Competitive landscape snapshot
Figure 12 Pharmaceutical market, (USD Billion)
Figure 13 Market dynamics
Figure 14 Porter’s five forces analysis
Figure 15 PESTLE analysis
Figure 16 Schizophrenia Drugs market: Drug Class Outlook and key takeaways
Figure 17 Schizophrenia Drugs market: Drug Class movement analysis
Figure 18 Second-Generation Antipsychotics market estimates and forecast, 2018-2030 (USD Million)
Figure 19 Risperdal (Risperidone) market estimates and forecast, 2018-2030 (USD Million)
Figure 20 Invega (Paliperidone) market estimates and forecast, 2018-2030 (USD Million)
Figure 21 Zyprexa (Olanzapine) market estimates and forecast, 2018-2030 (USD Million)
Figure 22 Geodon (Ziprasidone) market estimates and forecast, 2018-2030 (USD Million)
Figure 23 Seroquel (Quetiapine) market estimates and forecast, 2018-2030 (USD Million)
Figure 24 Latuda (Lurasidone) market estimates and forecast, 2018-2030 (USD Million)
Figure 25 Aristada (Aripiprazole Lauroxil) market estimates and forecast, 2018-2030 (USD Million)
Figure 26 Fanapt (Iloperidone) market estimates and forecast, 2018-2030 (USD Million)
Figure 27 Saphris (Asenapine) market estimates and forecast, 2018-2030 (USD Million)
Figure 28 Vraylar (Cariprazine) market estimates and forecast, 2018-2030 (USD Million)
Figure 29 Third-Generation Antipsychotics market estimates and forecast, 2018-2030 (USD Million)
Figure 30 Abilify (Aripiprazole) market estimates and forecast, 2018-2030 (USD Million)
Figure 31 Others market estimates and forecast, 2018-2030 (USD Million)
Figure 32 Schizophrenia Drugs market: Route of Administration Outlook and key takeaways
Figure 33 Schizophrenia Drugs market: Route of Administration movement analysis
Figure 34 Oral Antipsychotics market estimates and forecast, 2018-2030 (USD Million)
Figure 35 Injectable Antipsychotics market estimates and forecast, 2018-2030 (USD Million)
Figure 36 Schizophrenia Drugs market: Distribution Channel Outlook and key takeaways
Figure 37 Schizophrenia Drugs market: Distribution Channel movement analysis
Figure 38 Hospital Pharmacies market estimates and forecast, 2018-2030 (USD Million)
Figure 39 Retail Pharmacies market estimates and forecast, 2018-2030 (USD Million)
Figure 40 Online Pharmacies market estimates and forecast, 2018-2030 (USD Million)
Figure 41 Others market estimates and forecast, 2018-2030 (USD Million)
Figure 42 Schizophrenia Drugs market revenue, by region, 2024 & 2030, (USD Million)
Figure 43 Regional marketplace: Key takeaways
Figure 44 North America schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 45 Key country dynamics
Figure 46 Target disease prevalence
Figure 47 U.S. schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 48 Key country dynamics
Figure 49 Target disease prevalence
Figure 50 Canada schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 51 Mexico schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 52 Key country dynamics
Figure 53 Target disease prevalence
Figure 54 Europe schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 55 Key country dynamics
Figure 56 Target disease prevalence
Figure 57 UK schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 58 Key country dynamics
Figure 59 Target disease prevalence
Figure 60 Germany schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 61 Key country dynamics
Figure 62 Target disease prevalence
Figure 63 France schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 64 Key country dynamics
Figure 65 Target disease prevalence
Figure 66 Spain schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 67 Key country dynamics
Figure 68 Target disease prevalence
Figure 69 Italy schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 70 Key country dynamics
Figure 71 Target disease prevalence
Figure 72 Denmark schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 73 Key country dynamics
Figure 74 Target disease prevalence
Figure 75 Sweden schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 76 Key country dynamics
Figure 77 Target disease prevalence
Figure 78 Norway schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 79 Rest of Europe schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 80 Asia Pacific schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 81 Key country dynamics
Figure 82 Target disease prevalence
Figure 83 Japan schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 84 Key country dynamics
Figure 85 Target disease prevalence
Figure 86 China schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 87 Key country dynamics
Figure 88 Target disease prevalence
Figure 89 India schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 90 Key country dynamics
Figure 91 Target disease prevalence
Figure 92 Australia schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 93 Key country dynamics
Figure 94 Thailand schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 95 Key country dynamics
Figure 96 South Korea schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 97 Rest of Asia Pacific schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 98 Latin America schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 99 Key country dynamics
Figure 100 Target disease prevalence
Figure 101 Brazil schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 102 Key country dynamics
Figure 103 Target disease prevalence
Figure 104 Argentina schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 105 Rest of Latin America schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 106 MEA schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 107 Key country dynamics
Figure 108 Target disease prevalence
Figure 109 South Africa schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 110 Key country dynamics
Figure 111 Target disease prevalence
Figure 112 Saudi Arabia schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 113 Key country dynamics
Figure 114 Target disease prevalence
Figure 115 UAE schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 116 Key country dynamics
Figure 117 Target disease prevalence
Figure 118 Kuwait schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
Figure 119 Rest of MEA schizophrenia drugs market estimates and forecasts, 2018-2030 (USD Million)
